Table 4.
Median days of SARS-CoV-2 shedding, calculated from the day of antiviral drug onset according to different conditions.
| Remdesivir Cohort Ω SARS-CoV-2 Shedding |
Nirmatrelvir/Ritonavir Cohort Ω SARS-CoV-2 Shedding |
|||||
|---|---|---|---|---|---|---|
| Variable | Median Days (Range) |
n | p Value | Median Days (Range) |
n | p Value |
| Age | 0.25 | 0.87 | ||||
| • <41 years | 21 (2–32) | 7 | 17 (6–95) | 12 | ||
| • 41–60 years | 30 (2–162) | 55 | 20.5 (2–220) | 40 | ||
| • 61–70 years | 30 (1–208) | 32 | 17.5 (2–132) | 30 | ||
| • >71 years | 25 (2–108) | 34 | 21 (2–167) | 40 | ||
| SARS-CoV-2 infection severity | 0.013 | NT | ||||
| • Mild | 27 (2–162) | 91 | 20 (2–220) | 116 | ||
| • Moderate | 27.5 (3–108) | 16 | 7.5 (2–25) | 4 | ||
| • Severe | 39 (1–208) | 21 | 5 (2–8) | 2 | ||
| Fever | 0.035 | 0.83 | ||||
| • Yes | 32 (1–208) | 61 | 20 (2–122) | 42 | ||
| • No | 23 (2–162) | 67 | 19.5 (2–220) | 80 | ||
| Corticosteroids at infection | 0.82 | 0.13 | ||||
| • Yes | 31 (3–208) | 39 | 14.5 (2–75) | 32 | ||
| • No | 28 (1–162) | 89 | 21 (2–220) | 90 | ||
| Pneumonia | 0.022 | NT | ||||
| • Yes | 34 (1–208) | 37 | 7.5 (2–25) | 6 | ||
| • No | 27 (2–162) | 91 | 20.5 (2–220) | 116 | ||
| Hospital admission | 0.15 | 0.88 | ||||
| • Yes | 30 (1–117) | 69 | 25 (2–52) | 11 | ||
| • No | 24 (2–208) | 59 | 20 (2–220) | 111 | ||
| Oxygen requirement | 0.022 | 0.8 | ||||
| • Yes | 39 (1–208) | 21 | 5 (2–8) | 2 | ||
| • No | 26.5 (2–162) | 106 | 20 (2–220) | 120 | ||
| Monoclonal antibodies | 0.055 | 0.82 | ||||
| • Yes | 35 (7–162) | 26 | 20.5 (2–132) | 11 | ||
| • No | 25 (1–208) | 98 | 20 (2–220) | 111 | ||
| Convalescent plasma | 0.7 | 0.49 | ||||
| • Yes | 30 (4–106) | 24 | 25 (2–59) | 5 | ||
| • No | 28 (1–208) | 104 | 19 (2–220) | 117 | ||
| Corticosteroids for COVID-19 therapy | 0.004 | 0.11 | ||||
| • Yes | 37 (1–208) | 31 | 2 (2–25) | 3 | ||
| • No | 26 (2–117) | 97 | 20 (2–220) | 119 | ||
| Time from last therapy to COVID-19 | 0.49 | 0.87 | ||||
| • <6 months | 29 (1–162) | 104 | 19.5 (2–167) | 90 | ||
| • 6–12 months | 29 (11–62) | 9 | 18.5 (2–122) | 12 | ||
| • >12 months or not treated | 17 (3–208) | 15 | 22.5 (2–220) | 18 | ||
| Anti-CD20 | 0.015 | 0.34 | ||||
| • Yes | 33 (1–162) | 39 | 20 (2–220) | 59 | ||
| • No | 27 (2–208) | 89 | 20 (2–167) | 63 | ||
| Time from anti-CD 20 to COVID-19 | 0.027 | 0.69 | ||||
| • <6 months | 34 (1–162) | 32 | 20 (6–132) | 49 | ||
| • 6–12 months | 67.5 (62–73) | 2 | 32 (2–63) | 2 | ||
| • >12 months | 29 (7–63) | 5 | 16 (2–220) | 8 | ||
| • Not treated | 27 (2–208) | 89 | 20 (2–167) | 63 | ||
| B-cell NHL/CLL vs. others | 0.005 | 0.61 | ||||
| • Yes | 33 (1–162) | 49 | 19.5 (2–220) | 64 | ||
| • No | 25 (2–208) | 79 | 20.5 (2–167) | 58 | ||
| Ct value at diagnosis * | 0.001 | 0.82 | ||||
| • ≥20 | 19 (2–108) | 49 | 19 (2–90) | 28 | ||
| • <20 | 38 (1–208) | 47 | 21 (5–95) | 34 | ||
| ATV onset from the first positive PCR | 0.008 | 0.6 | ||||
| • <5 days | 27.5 (2–208) | 100 | 20 (2–167) | 110 | ||
| • ≥5 days | 31 (1–162) | 28 | 20.5 (2–220) | 12 | ||
| Duration of ATV | 0.001 | 0.83 | ||||
| • <5 days | 19 (2–89) | 42 | 21 (20–21) | 2 | ||
| • 5 days | 33 (1–208) | 52 | 19 (2–220) | 108 | ||
| • >5 days | 31.5 (4–108) | 34 | 24 (4–132) | 12 | ||
| Co-infections | 0.34 | 0.63 | ||||
| • Yes | 34 (2–208) | 17 | 38 (13–63) | 2 | ||
| • No | 27 (1–162) | 111 | 20 (2–220) | 120 | ||
| ANC < 0.5 × 109/L | 0.4 | 0.25 | ||||
| • Yes | 38 (2–108) | 11 | 14 (6–51) | 5 | ||
| • No | 30 (1–117) | 77 | 24 (2–122) | 49 | ||
| ALC < 0.5 × 109/L | 0.1 | 0.81 | ||||
| • Yes | 35 (2–117) | 36 | 20.5 (2–122) | 18 | ||
| • No | 27 (1–90) | 52 | 23 (2–95) | 36 | ||
| Vaccination status | 0.039 | 0.28 | ||||
| • Complete | 31 (1–208) | 82 | 20 (2–220) | 93 | ||
| • Incomplete | 24.5 (2–90) | 46 | 18 (2–167) | 29 | ||
Abbreviations: NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; Ct, PCR cycle threshold; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NT, not tested. Ω Median duration of SARS-CoV-2 detection estimated from the day of antiviral onset in the remdesivir cohort was 28.5 days (range 1–208), whereas in the nirmatrelvir/ritonavir cohort, it was 20 days (range 3–220) (p = 0.004). * These variables have not been tested since there is a lack of data in more than 40% of cases.